Vaxcyte Vaccine Passes Phase 3 Trial, Challenging Pfizer and Merck
The biotech firm's pneumococcal shot met primary endpoints in the OPUS-1 trial, matching or beating competitors' products on nearly all measured strains.
The story so far
2 publishers have covered this in 4 articles since 5 Oct 2026. STAT published first, on 5 October at 12:19 UTC; Quartz followed 24h 25m later. The most recent article, from Quartz, appeared on 6 October at 12:50 UTC.
Outlets reporting it: STAT, Quartz.
No prediction market is linked to this story at the moment. We match each story to Polymarket and Kalshi markets by what they ask, and show one only when it is close enough to be useful; if a market on this topic opens, it will appear here. Meanwhile, browse every market we track or see how stories and markets are matched.
How it unfolded
Every source in the order it published.
- STATSTAT+: Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine market
- STATSTAT+: Pharmalittle: We’re reading about a Vaxcyte pneumococcal shot, increasing pharma M&A, and more
- QuartzVaxcyte stock surged after its pneumococcal vaccine passed a key phase 3 test
- QuartzDie Aktie von Vaxcyte stieg stark an, nachdem ihr Pneumokokken-Impfstoff einen wichtigen Phase-3-Test bestanden hatte.
Sources
Every article we clustered into this story. Headlines link to the publisher.
- Die Aktie von Vaxcyte stieg stark an, nachdem ihr Pneumokokken-Impfstoff einen wichtigen Phase-3-Test bestanden hatte. Quartz
- Vaxcyte stock surged after its pneumococcal vaccine passed a key phase 3 test Quartz
- STAT+: Pharmalittle: We’re reading about a Vaxcyte pneumococcal shot, increasing pharma M&A, and more STAT
- STAT+: Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine market STAT
In this story
- Vaxcyte
- Pfizer
- Merck